High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Open Access
- 18 November 2025
- journal article
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
Abstract
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.Keywords
This publication has 29 references indexed in Scilit:
- Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNPRhinology journal, 2021
- Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polypsInternational Forum of Allergy & Rhinology, 2021
- European Position Paper on Rhinosinusitis and Nasal Polyps 2020Rhinology journal, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Eosinophilic chronic rhinosinusitisAllergology International, 2019
- JESREC score and mucosal eosinophilia can predict endotypes of chronic rhinosinusitis with nasal polypsAuris Nasus Larynx, 2019
- Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic reviewRhinology journal, 2018
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Eosinophilic rhinosinusitis is not a disease of ostiomeatal occlusionThe Laryngoscope, 2013
- Staging in rhinosinusitus.1993